Pat Fulgham
Urology · Dallas, TXNPI 1295788206
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AstraZeneca at 29.7% of the total. 2025 is the largest year on record at $8,482, more than ten times the $85 reported in 2019.
Across 78 payments — averaging $190.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- EDAP Technomed Inc$2K
- Telix Pharmaceuticals$2K
- Profound Medical Corp.$2K
- Johnson & Johnson$2K
- Janssen Scientific Affairs, LLC$1K
- plus $2K from 22 others
Across 23 payments — averaging $6934.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blue Earth Diagnostics$160K
What the payments were for
- Consulting fees$7,30749%
- Travel & lodging$3,72925%
- Food & beverage$3,78826%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $4,409 |
| EDAP Technomed Inc | 6 | $2,250 |
| Telix Pharmaceuticals | 12 | $1,714 |
| Profound Medical Corp. | 4 | $1,607 |
| Johnson & Johnson(2 entities) | 7 | $1,524 |
| Janssen Scientific Affairs, LLC | 4 | $1,319 |
| Bayer | 1 | $872 |
| AbbVie | 8 | $149 |
| Tempus AI, Inc | 2 | $141 |
| Histosonics, Inc. | 1 | $140 |
| Bioprotect Medical, Inc. | 2 | $127 |
| Blue Earth Diagnostics | 4 | $75 |
| Innovation Technologies Inc | 2 | $73 |
| Pfizer | 4 | $69 |
| Novartis | 2 | $66 |
| Astellas Pharma US Inc | 3 | $58 |
| Sumitomo Pharma America, Inc. | 1 | $41 |
| Biotissue Holdings Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Procept Biorobotics Corporation | 1 | $23 |
| Myovant Sciences Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $16 |
| Merck | 1 | $15 |
| Coloplast | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,836 in reported general payments places this provider in the 80th percentile of 878 urology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 53 | $743 |
| Finasteride | 28 | $337 |
Paid to pharmacies, not to this prescriber.
Other urology in Dallas
- Allen MoreyDallas$914K
- Vitaly MargulisDallas$555K
- Yair LotanDallas$371K
- Claus RoehrbornDallas$169K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.